Clinical Trials Browser

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT07097142 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

486 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06263153 2025-12-17

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Phase 2 Recruiting

24 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

Phase 2 Recruiting

70 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06421142 2025-09-15

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

Phase NA Recruiting

80 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Phase 1 Recruiting

30 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

NCT06537154 2025-07-30

NEO-BLAST

Phase 2/3 Recruiting

688 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Phase 2 Recruiting

25 enrolled

Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03007719 2020-01-21

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Phase 2 Terminated

4 enrolled 8 charts

Genitourinary

Urinary Bladder Neoplasms

NCT02203136 2019-05-22

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

Completed

16 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT00612326 2015-12-18

Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging

Completed

26 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

Phase NA Terminated

10 enrolled 3 charts

Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

Clinical Trials

TRIFECTA

GAIN-BCG

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

FAPI PET RDRC

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

RECIPE-B1

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NEO-BLAST

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast